Long Term Dasatinib Safe, Effective Against CML

Share this content:

(ChemotherapyAdvisor) – Long-term treatment with dasatinib is safe and efficacious in patients with imatinib-resistant, chronic phase chronic myeloid leukemia (CP-CML), according to an international team of researchers. This conclusion is based on an abstract entitled “Six-year Follow-up of Patients with Imatinib-resistant or Imatinib-intolerant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Dasatinib,” which was presented at the 17th Congress of the European Hematological Association in Amsterdam, The Netherlands.

Recommended dosing for dasatinib is 100mg once daily, based on the CA180-034 dose-optimization study. Six-year analysis of that study provides the longest follow-up of patients with CP-CML resistant or intolerant to imatinib, noted lead author Delphine Rea, MD, of Hôpital Saint-Louis, Paris, France. In this study, patients (N=670) were randomized to dasatinib 100mg once-daily (n=167), 50mg twice daily (n=167), 140mg once daily (n=168), or 70mg twice daily (n=168), and followed for up to six years.

At six months, 85% and 83% of patients achieved a major molecular response (MMR) and complete cytogenetic response (CCyR) at six months; 85% and 79% of patients achieving MMR and CCyR at 12 months were alive and progression-free at five years, respectively. For 100mg once daily, grade 3/4 hematologic adverse events (AEs) generally first occurred within 12 months of treatment and all-grade non-hematologic AEs generally first occurred within 24 months of treatment. Five-year rates of non-hematologic AEs (all-grades) for 100mg once daily vs other treatment arms include headache (33% vs. 28%), diarrhea (28% vs. 31%), fatigue (26% vs 23%), and pleural effusion (24% vs. 32%). Dose/schedule modifications were permitted to manage AEs.

The investigators concluded that “the majority of patients receiving dasatinib after five years continue on once-daily dosing. Long-term follow-up of dasatinib 100mg once daily demonstrates durable efficacy and a generally well-tolerated safety profile for patients with CP-CML following prior imatinib therapy.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs